V. Fernandez, O. Salamero, B. Espinet, F. Sole, C. Royo et al., Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma, Cancer Research, vol.70, issue.4, pp.1408-1418, 2010.
DOI : 10.1158/0008-5472.CAN-09-3419

W. Hofmann, S. De-vos, K. Tsukasaki, W. Wachsman, G. Pinkus et al., Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray, Blood, vol.98, issue.3, pp.787-794, 2001.
DOI : 10.1182/blood.V98.3.787

N. Martinez, F. Camacho, P. Algara, A. Rodriguez, A. Dopazo et al., The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival, Cancer Res, vol.63, pp.8226-8232, 2003.

E. Ortega-paino, J. Fransson, S. Ek, and C. Borrebaeck, Functionally associated targets in mantle cell lymphoma as defined by DNA microarrays and RNA interference, Blood, vol.111, issue.3, pp.1617-1624, 2008.
DOI : 10.1182/blood-2007-02-068791

M. Pinyol, S. Bea, L. Pla, V. Ribrag, J. Bosq et al., Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis, Blood, vol.109, issue.12, pp.5422-5429, 2007.
DOI : 10.1182/blood-2006-11-057208

A. Rinaldi, I. Kwee, M. Taborelli, C. Largo, S. Uccella et al., Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma, British Journal of Haematology, vol.64, issue.3, pp.303-316, 2006.
DOI : 10.1111/j.1365-2141.2005.05883.x

E. Rizzatti, R. Falcao, R. Panepucci, R. Proto-siqueira, W. Anselmo-lima et al., Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways, British Journal of Haematology, vol.104, issue.4, pp.516-526, 2005.
DOI : 10.1186/1471-213X-2-8

A. Rosenwald, G. Wright, A. Wiestner, W. Chan, J. Connors et al., The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma, Cancer Cell, vol.3, issue.2, pp.185-197, 2003.
DOI : 10.1016/S1535-6108(03)00028-X

B. Coiffier, F. Berger, and R. Houlgatte, Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct geneexpression profiles allowing molecular diagnosis, Blood, vol.103, pp.2727-2737, 2004.

R. Davis, V. Ngo, G. Lenz, P. Tolar, R. Young et al., Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma, Nature, vol.14, issue.7277, pp.88-92, 2010.
DOI : 10.1038/nature08638

P. Deglesne, N. Chevallier, R. Letestu, F. Baran-marszak, T. Beitar et al., Survival Response to B-Cell Receptor Ligation Is Restricted to Progressive Chronic Lymphocytic Leukemia Cells Irrespective of Zap70 Expression, Cancer Research, vol.66, issue.14, pp.7158-7166, 2006.
DOI : 10.1158/0008-5472.CAN-06-0085

A. Rodriguez, R. Villuendas, L. Yanez, M. Gomez, R. Diaz et al., Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlation, Leukemia, vol.93, issue.9, pp.1984-1991, 2007.
DOI : 10.1182/blood-2002-06-1683

F. Baran-marszak, M. Boukhiar, S. Harel, C. Laguillier, C. Roger et al., Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma, Haematologica, vol.95, issue.11, pp.1865-1872, 2010.
DOI : 10.3324/haematol.2009.019745

C. Pighi, T. Gu, I. Dalai, S. Barbi, C. Parolini et al., Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling, Cellular Oncology, vol.4, issue.2, pp.141-153, 2011.
DOI : 10.1007/s13402-011-0019-7

A. Hadzidimitriou, A. Agathangelidis, N. Darzentas, F. Murray, M. Delfau-larue et al., Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases, Blood, vol.118, issue.11, pp.3088-3095, 2011.
DOI : 10.1182/blood-2011-03-343434

S. Pierce and W. Liu, The tipping points in the initiation of B cell signalling: how small changes make big differences, Nature Reviews Immunology, vol.174, issue.11, pp.767-777, 2010.
DOI : 10.1038/nri2853

L. Platanias, Map kinase signaling pathways and hematologic malignancies, Blood, vol.101, issue.>12, pp.4667-4679, 2003.
DOI : 10.1182/blood-2002-12-3647

A. Alizadeh, M. Eisen, R. Davis, C. Ma, I. Lossos et al., Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling, Nature, vol.303, issue.6769, pp.503-511, 2000.
DOI : 10.1038/35000501

T. Hideshima, T. Hayashi, D. Chauhan, M. Akiyama, P. Richardson et al., Biologic sequelae of c-Jun NH2-terminal kinase (JNK) activation in multiple myeloma cell lines, Oncogene, vol.22, issue.54, pp.8797-8801, 2003.
DOI : 10.1038/sj.onc.1206919

M. Wang, C. Atayar, S. Rosati, A. Bosga-bouwer, P. Kluin et al., JNK is constitutively active in mantle cell lymphoma: cell cycle deregulation and polyploidy by JNK inhibitor SP600125, The Journal of Pathology, vol.29, issue.1, pp.95-103, 2009.
DOI : 10.1002/path.2521

J. Ke, M. Gururajan, A. Kumar, A. Simmons, L. Turcios et al., The Role of MAPKs in B Cell Receptor-induced Down-regulation of Egr-1 in Immature B Lymphoma Cells, Journal of Biological Chemistry, vol.281, issue.52, pp.39806-39818, 2006.
DOI : 10.1074/jbc.M604671200

S. Muthukkumar, S. Han, V. Rangnekar, and S. Bondada, Role of Egr-1 Gene Expression in B Cell Receptor-induced Apoptosis in an Immature B Cell Lymphoma, Journal of Biological Chemistry, vol.272, issue.44, pp.27987-27993, 1997.
DOI : 10.1074/jbc.272.44.27987

D. Forsdyke, cDNA cloning of mRNAS which increase rapidly in human lymphocytes cultured with concanavalin-A and cycloheximide, Biochemical and Biophysical Research Communications, vol.129, issue.3, pp.619-625, 1985.
DOI : 10.1016/0006-291X(85)91936-9

Z. Wang, D. Morris, and T. Rothstein, Constitutive and Inducible Levels of egr-1 and c-myc Early Growth Response Gene Expression in Self-Renewing B-1 Lymphocytes, Cellular Immunology, vol.162, issue.2, pp.309-314, 1995.
DOI : 10.1006/cimm.1995.1083

J. Deligio and D. Zorio, Early growth response 1 (EGR1): A gene with as many names as biological functions, Cancer Biology & Therapy, vol.8, issue.20, pp.1889-1892, 2009.
DOI : 10.4161/cbt.8.20.9804

M. Gururajan, R. Chui, A. Karuppannan, J. Ke, and C. Jennings, c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells, Blood, vol.106, issue.4, pp.1382-1391, 2005.
DOI : 10.1182/blood-2004-10-3819

S. Tauzin, H. Ding, D. Burdevet, B. Borisch, and D. Hoessli, Membrane-associated signaling in human B-lymphoma lines, Experimental Cell Research, vol.317, issue.2, pp.151-162, 2011.
DOI : 10.1016/j.yexcr.2010.09.011

S. Sato, H. Sanjo, K. Takeda, J. Ninomiya-tsuji, M. Yamamoto et al., Essential function for the kinase TAK1 in innate and adaptive immune responses, Nature Immunology, vol.165, issue.11, pp.1087-1095, 2005.
DOI : 10.1093/intimm/dxf046

N. Williams, I. Lucet, S. Klinken, E. Ingley, and J. Rossjohn, Crystal Structures of the Lyn Protein Tyrosine Kinase Domain in Its Apo- and Inhibitor-bound State, Journal of Biological Chemistry, vol.284, issue.1, pp.284-291, 2009.
DOI : 10.1074/jbc.M807850200

D. Gomez-martin, M. Diaz-zamudio, M. Galindo-campos, and J. Alcocer-varela, Early growth response transcription factors and the modulation of immune response, Autoimmunity Reviews, vol.9, issue.6, pp.454-458, 2009.
DOI : 10.1016/j.autrev.2009.12.006

V. Seyfert, S. Mcmahon, W. Glenn, X. Cao, V. Sukhatme et al., Egr-1 expression in surface Ig-mediated B cell activation. Kinetics and association with protein kinase C activation, J Immunol, vol.145, pp.3647-3653, 1990.

A. Gashler and V. Sukhatme, Early Growth Response Protein 1 (Egr-1): Prototype of a Zinc-finger Family of Transcription Factors, Prog Nucleic Acid Res Mol Biol, vol.50, pp.191-224, 1995.
DOI : 10.1016/S0079-6603(08)60815-6

J. Maltzman, J. Carman, and J. Monroe, Role of EGR1 in regulation of stimulus-dependent CD44 transcription in B lymphocytes., Molecular and Cellular Biology, vol.16, issue.5, pp.2283-2294, 1996.
DOI : 10.1128/MCB.16.5.2283

S. Mcmahon and J. Monroe, The role of early growth response gene 1 (egr-1) in regulation of the immune response, J Leukoc Biol, vol.60, pp.159-166, 1996.

D. Buglio, S. Palakurthi, K. Byth, F. Vega, D. Toader et al., Essential role of TAK1 in regulating mantle cell lymphoma survival, Blood, vol.120, issue.2, pp.347-355, 2012.
DOI : 10.1182/blood-2011-07-369397

H. Tagawa, S. Karnan, R. Suzuki, K. Matsuo, X. Zhang et al., Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM, Oncogene, vol.24, issue.8, pp.1348-1358, 2005.
DOI : 10.1038/sj.onc.1208300

L. Vallat, Y. Park, C. Li, and J. Gribben, Temporal genetic program following B-cell receptor cross-linking: altered balance between proliferation and death in healthy and malignant B cells, Blood, vol.109, issue.9, pp.3989-3997, 2007.
DOI : 10.1182/blood-2006-09-045377

S. Han, S. Chung, D. Robertson, R. Chelvarajan, and S. Bondada, CpG oligodeoxynucleotides rescue BKS-2 immature B cell lymphoma from anti-IgM-mediated growth inhibition by up-regulation of egr-1, International Immunology, vol.11, issue.6
DOI : 10.1093/intimm/11.6.871

S. Tauzin, H. Ding, K. Khatib, I. Ahmad, D. Burdevet et al., Oncogenic association of the Cbp/PAG adaptor protein with the Lyn tyrosine kinase in human B-NHL rafts, Blood, vol.111, issue.4, pp.2310-2320, 2008.
DOI : 10.1182/blood-2007-05-090985

R. Boyd, J. , R. Walewska, R. Brown, D. Dyer et al., Protein Profiling of Plasma Membranes Defines Aberrant Signaling Pathways in Mantle Cell Lymphoma, Molecular & Cellular Proteomics, vol.8, issue.7, pp.1501-1515, 2009.
DOI : 10.1074/mcp.M800515-MCP200

C. Yang, P. Lu, F. Lee, A. Chadburn, J. Barrientos et al., Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib, Leukemia, vol.177, issue.9, pp.1755-1766, 2008.
DOI : 10.1038/sj.onc.1209510

F. Luo, Z. Yang, A. Camuso, R. Smykla, K. Mcglinchey et al., Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure, Clinical Cancer Research, vol.12, issue.23, pp.7180-7186, 2006.
DOI : 10.1158/1078-0432.CCR-06-1112

P. Amrein, E. Attar, T. Takvorian, E. Hochberg, K. Ballen et al., Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia, Clinical Cancer Research, vol.17, issue.9, pp.2977-2986, 2011.
DOI : 10.1158/1078-0432.CCR-10-2879

R. Houot, L. Gouill, S. , O. Uribe, M. Mounier et al., Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS, Annals of Oncology, vol.23, issue.6, pp.1555-1561, 2012.
DOI : 10.1093/annonc/mdr450

URL : https://hal.archives-ouvertes.fr/hal-00744066

H. Peng, L. Chong, H. Chiang, and B. Chiang, Establishment and characterization of a new human lymphoma-derived cell line, p.2